Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00848926 · OUTCOME

Area Under the Curve

A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma · Source last updated 2017-03-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
GEOMETRIC_MEAN
Unit
day * microgram/mL
Interval / dispersion
Geometric Coefficient of Variation
Time frame
3 weeks

What was measured

Area under the serum concentration-time curve from time 0 to 21 days following the first dose of brentuximab vedotin

Analysis population: All participants who received treatment

Groups in this outcome

Brentuximab Vedotin

Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Brentuximab Vedotin102

Reported measurements

Source class 1
Values in day * microgram/mL · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Brentuximab Vedotin8846Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        46
        value
        88
denoms
  1. counts
    1. group Id
      OG000
      value
      102
    units
    Participants
description
Area under the serum concentration-time curve from time 0 to 21 days following the first dose of brentuximab vedotin
dispersion Type
Geometric Coefficient of Variation
groups
  1. description
    Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
    id
    OG000
    title
    Brentuximab Vedotin
param Type
GEOMETRIC_MEAN
population Description
All participants who received treatment
reporting Status
POSTED
time Frame
3 weeks
title
Area Under the Curve
type
SECONDARY
unit Of Measure
day * microgram/mL

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice